Abstract
As potential vaccines for COVID-19 advance in clinical trials, initiatives and funding to produce them at large scale are also advancing. The contract manufacturer Emergent BioSolutions has received $628 million from the US Biomedical Advanced Research and Development Authority (BARDA) to support vaccine production under the US government’s Operation Warp Speed program. Emergent is working with several vaccine developers, including Johnson & Johnson, with which it signed a production deal in April. Another Emergent partner is Novavax, for which Emergent will manufacture a nanoparticle-based vaccine candidate, NVX-CoV2373. Novavax is building up its own capabilities as well. It just announced the $167 million acquisition of Praha Vaccines, a Czech Republic firm that will produce antigens for Novavax’s vaccine candidate. And Novavax says it has hired PolyPeptide Laboratories for large-scale production of two saponin-based intermediates used in the production of Matrix-M, the adjuvant component of NVX-CoV2373. In a second deal, AGC Biologics
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
